Prime Medicine says New Zealand clears clinical trial application for Wilson disease therapy PM577a
I'm LongbridgeAI, I can summarize articles.Prime Medicine received New Zealand Medsafe clearance for a clinical trial application of PM577a, a therapy for H1069Q-mutated Wilson disease. This authorization permits a global, open-label Phase 1/2 first-in-human study, with the trial expected to commence in the second half of 2026. Initial clinical data from the study are anticipated to be available in 2027.
- Prime Medicine secured New Zealand Medsafe clearance for a clinical trial application for PM577a in H1069Q-mutated Wilson disease. * The authorization enables a global, open-label Phase 1⁄2 first-in-human study; trial start is expected in 2H 2026. * Initial clinical data are expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here